- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01159418
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
A Phase IB Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) Given Orally in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors
연구 개요
상세 설명
The combination of Carboplatin (C) and Paclitaxel (PTX) is considered standard treatment in patients with epithelial ovarian cancer and endometrial cancer, in USA and in those in whom anthracyclines are not recommended. In cervical cancer, where very often the renal function is impaired, C represents a convenient substitute of cisplatin in the combination with PTX; in NSCLC the C and PTX regimen is first choice therapy for outpatient treatment first or second line.
LBH is a histone deacetylase (HDAC) inhibitor available also for oral administration.
In combination with platinum agents LBH589 could improve efficacy on DNA by multiple non-exclusive mechanisms (by increasing drug access to chromosomal DNA, interfering with DNA repair, modulating the levels of pro antiapoptotic genes or proliferation/survival genes).
The inclusion of Paclitaxel in the combination of LBH589 and Carboplatin is supported by the results already available with the combination of the HDAC inhibitor Vorinostat (suberoylanilide hydroxamic acid) given orally with carboplatin (AUC 6 mg/ml.h) and paclitaxel (200 mg/m2) in a Phase I study in patients with solid tumors. The regimen proved to be feasible, well tolerated and was associated with promising antitumor activity in patients with NSCLC.
The mechanism of action, and the preliminary preclinical data, suggest that the combination of LBH589, Carboplatin and Paclitaxel could be feasible and worthy of clinical investigation.
연구 유형
등록 (예상)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Basel, 스위스, 4031
- Huniversitätsspitals Basel
-
Bellinzona, 스위스, 6500
- Istituto Oncologico della Svizzera Italiana
-
Lausanne, 스위스, 1011
- Mèdecin Adjoint, ME - CePO, CHUV
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histological/cytological diagnosis of solid tumors in which treatment with Carboplatin and Paclitaxel is indicated, e.g. NSCLC, GY tumors, prostate cancer, unknown primary
- Progressive disease (also in terms of tumor markers only, like CA 125 for ovary and PSA for prostate).
- Age 18-75 years
- Prior chemotherapy of ≤ 1 line for advanced disease
- ECOG Performance Status < 2
- Life expectancy of at least 3 months
- The patient must be able to read, understand and provide written evidence of informed consent
- Female patients may not be pregnant or lactating and must be willing to practice contraception. The effects of LBH589 on the developing human fetus are unknown. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation.
- Male patients that are not surgically sterile must be practicing a medically acceptable contraceptive regimen while on study treatment
Adequate organ function as defined by the following:
- ANC > 1500/µL
- Platelets ≥ 100,000/µL
- Haemoglobin ≥ 10 g/dl
- Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 60 ml/min
- Magnesium, potassium and phosphorus ≥ the lower limit of normal or correctable with supplements
- Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 x ULN or ≤ 5.0 x ULN if hepatic involvement is present
- Serum bilirubin ≤ 1.5 x ULN
- Alkaline phosphatase (ALP) ≤ 2.5 x ULN or ALP > 2.5 x UNL with liver fraction ≤ 2.5 x ULN
Exclusion Criteria:
- Other chemotherapy treatment < 4 weeks prior to enrolment
- Hypersensitivity or allergic reactions to platinum compounds or Carboplatin®; hypersensitivity or allergic reactions to Paclitaxel
- Radiotherapy involving > 30% of the active bone marrow
- Radiotherapy < 4 weeks prior to enrolment
- Pre-existing peripheral neuropathy ≥ grade 2
- Pre-existing CTCAE hearing loss or tinnitus ≥ grade 2
- Symptomatic pleural effusion
- Clinically significant third space fluid accumulation (e.g. ascites,..)
- Symptomatic brain metastasis or meningeal tumors
- Patients who have not recovered (> grade 1) from the following toxicities of previous regimens before enrolment: fatigue, mucositis, nausea/vomiting, diarrhea
- Concurrent enrolment, or previous enrolment within 30 days prior to registration in another investigational device or drug trial(s) or is receiving other investigational agent(s)
- Human immunodeficiency virus (HIV) infection
- History of bone marrow or major organ transplant
- Prior high dose treatment with PBSC support
Impaired cardiac function, including any one of the followings:
- Complete Left Bundle Branch Block or obligate use of a cardiac pacemaker or congenital long QT syndrome or history or presence of atrial or ventricular tachyarrhythmias or clinically significant resting bradycardia (< 50 beats per minute) or QTcF > 480 msec on screening ECG or Right Bundle Branch block + left anterior hemiblock (bifascicular block)
- Angina pectoris or acute MI ≤ 3 months prior to starting study drug
- Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, malabsorption syndrome, or small bowel resection)
- Acute or chronic liver or renal disease
- Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection, chronic obstructive or chronic restrictive pulmonary disease) that could cause unacceptable safety risks or compromise compliance with the protocol
- Concomitant use of CYP3A4/5 inhibitors or inducers where the treatment can not be discontinued or switched to a different medication prior to starting study drug (medications listed in Appendix 3). The medications listed in Appendix 3 have a relative risk of prolonging the QT interval or inducing Torsades de Pointes, but do not represent an exclusion criteria
- Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GMCSF) ≤ 2 weeks prior to starting study drug.
- Treatment with therapeutic doses of sodium warfarin (Coumarin ). Low doses of Coumarin (e.g., ≤ 2 mg/day) for line patency is allowable
- Patients who have received biologic therapy (excluding antiangiogenics) or immunotherapy ≤ 2 weeks prior to starting study treatment or who have not recovered from side effects of such therapy
- Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- Unable or unwilling to comply with all study procedures
- Current history of alcohol or drug abuse
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Panobinostat (LBH589), Carboplatin and Paclitaxel
|
The treatment will be repeated every three weeks until disease progression. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Maximum Tolerated Dose (MTD) Recommended Dose (RD)
기간: 3 weeks after the first drug administration (1 Cycle)
|
Number of Dose-Limiting Tocixities (DLTs)
|
3 weeks after the first drug administration (1 Cycle)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Hints of antitumor activity
기간: from first drug administration until tumor progression (every 6 weeks)
|
objective tumor responses based on RECIST criteria
|
from first drug administration until tumor progression (every 6 weeks)
|
Biomarkers of HDAC
기간: Cycle 1 on day 1, 4, 8, 15 and Cycle 2 on day 1, 8.
|
acetylation of histones, H3, H4 and tubulin in PBMC
|
Cycle 1 on day 1, 4, 8, 15 and Cycle 2 on day 1, 8.
|
Safety and tolerability
기간: 4 weeks after last drug administration
|
AE types and frequency monitored by laboratory and instrumental assessments, and physical examination
|
4 weeks after last drug administration
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SKSD00702
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
고급 고형 종양에 대한 임상 시험
-
Töölö HospitalTurku University Hospital; Tampere University Hospital; Jyväskylä Central Hospital; Kymenlaakso...모병
-
Advanced Bionics완전한심한 청력 손실 | Advanced Bionics HiResolution™ Bionic Ear System의 성인 사용자미국
-
University of AlbertaArthritis Society Canada; Wrist Evaluation Canada (WECAN)모병관절염 | 관절 질환 | 근골격계 질환 | 외상 후; 관절염 | 손목 관절염 | 주상골 불유합 | Scapholunate Advanced Collapse | 손목 관절병증캐나다
-
Extremity Medical모병골관절염 | 염증성 관절염 | 손목 터널 증후군(CTS) | 외상 후 관절염 | SLAC(Scapholunate Advanced Collapse) | Scapholunate Crystalline Advanced Collapse(SCAC) | 주상골, 사다리꼴 및 사다리꼴 고급 붕괴(STTAC) | Kienbock의 성인병 | 방사형 부정합 | 척골 전좌 | 주상골 불유합 진행성 허탈(SNAC)미국
-
AstraZeneca모병Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, 위암, 유방암 및 난소암스페인, 미국, 벨기에, 영국, 프랑스, 헝가리, 캐나다, 대한민국, 호주
Panobinostat (LBH589), Carboplatin and Paclitaxel에 대한 임상 시험
-
Wenjun Cheng아직 모집하지 않음조직학적 유형에 따른 신생물 | 부위별 신생물 | 암종 | 신생물, 선상 및 상피 | 생식기 신생물, 여성 | 내분비계 질환 | 난소 질환 | 난소 신생물 | 나팔관 신생물 | 암종, 난소 상피 | 혈관신생 | 생식기 질환, 여성 | 항종양제 | 안로티닙 | 티로신 키나제 억제제
-
Peking UniversityMerck Sharp & Dohme LLC; Cancer Institute and Hospital, Chinese Academy of Medical Sciences 그리고 다른 협력자들모병
-
Shanghai Chest Hospital아직 모집하지 않음
-
Shanghai Henlius Biotech아직 모집하지 않음